Document Detail


Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
MedLine Citation:
PMID:  16607649     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anemia is the most common cytopenia associated with myelodysplastic syndromes (MDS). Current management relies on frequent red blood cell (RBC) transfusions and erythroid growth factors to alleviate symptoms. However, the dependence of patients with MDS on repeated RBC transfusions often results in significant clinical and economic consequences, poorer outcomes, and diminished health-related quality of life. In addition, the intensity and duration of RBC transfusion dependence can influence responses to treatment after disease progression. Erythropoietic growth factors may alleviate the need for RBC transfusions in some patients with MDS, although only a minority of patients experience responses. Emerging treatment strategies to reduce or eliminate the need for RBC transfusions in patients with MDS include immunomodulating drugs, immunosuppressive therapy, and differentiating agents. The immunomodulating drug lenalidomide in patients who have MDS with 5q deletion is unique among emerging approaches, in that cytogenetic remitting activity and durable erythroid responses have been achieved. Newer treatments have the potential to improve the care of patients with MDS by alleviating the clinical, economic, and quality-of-life consequences of long-term RBC transfusion dependence.
Authors:
Lodovico Balducci
Related Documents :
12744559 - Correlates of emergency response interval and mortality from severe anaemia in childhood.
23132189 - Sexual dysfunction in obsessive compulsive disorder and panic disorder.
2360589 - The prevalence of substance abuse in patients with suspected preterm labor.
22747509 - Admission time is associated with outcome of upper gastrointestinal bleeding: results o...
2498969 - Chronic liver disease. a case control study of the effect of previous blood transfusion.
2680679 - Clinical evaluation of w14859 (liquid thrombin) on upper gastro-intestinal haemorrhage-...
9651059 - Mediastinal lymphadenopathy in cryptogenic fibrosing alveolitis: the effect of steroid ...
12703019 - Magnetic resonance imaging findings of machado-joseph disease: histopathologic correlat...
21227939 - Management of fertility preservation in prepubertal patients: 5 years' experience at th...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Cancer     Volume:  106     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-03     Completed Date:  2006-06-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2087-94     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2006 American Cancer Society
Affiliation:
Department of Interdisciplinary Oncology, Geriatric Section, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA. balducci@moffitt.usf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anemia / diagnosis,  mortality,  therapy
Disease Progression
Erythrocyte Transfusion / methods*
Female
Humans
Immunosuppressive Agents / therapeutic use
Male
Middle Aged
Myelodysplastic Syndromes / diagnosis*,  mortality,  therapy*
Prognosis
Quality of Life*
Risk Assessment
Severity of Illness Index
Sickness Impact Profile
Survival Analysis
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  After prostate cancer: predictors of well-being among long-term prostate cancer survivors.
Next Document:  Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.